CellSource Co Ltd

CellSource maintains a strong liquidity position, with cash and equivalents amounting to ¥4.599 billion, representing 66.8% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is robust, supported by a current ratio of 9.53 and zero long-term debt. This positions the firm with minimal liquidity risk, as reflected in the low liquidity risk rating.

Profitability metrics indicate a relatively modest return profile. The company's return on equity (ROE) of 2.56% and return on assets (ROA) of 2.27% lag behind the industry median for pharmaceuticals, which typically exceeds 10% ROE. Gross margin of 62.7% is in line with industry norms, but operating margin of 7.2% is below the median for the sector, suggesting operational inefficiencies or competitive pricing pressures.

Geographically, CellSource's revenue is concentrated in Japan, with no disclosed international segments. The company's business model is heavily dependent on domestic healthcare demand and regulatory approvals, which increases exposure to local economic and policy shifts. No material revenue diversification is evident in the latest financial disclosures.

Growth expectations are modest, with no significant revenue acceleration in the current fiscal year. The company's operating income has remained flat YoY, and capital expenditures have been negative, indicating a focus on cost control rather than expansion. Analysts have assigned a mean price target of ¥880, a 156% premium to the current market price of ¥343, but this is based on a single "hold" recommendation with no strong buy or buy ratings.

Risk factors include limited diversification and reliance on a narrow product portfolio. The company has no immediate dilution risks, with basic and diluted shares outstanding aligned at 19.85 million. No recent equity issuance or ATM/shelf registration activity has been disclosed, and the risk assessment flags no dilution pressures in the near term.

Recent filings and transcripts show no material changes in business strategy or product pipeline. The company continues to focus on its core regenerative medicine platform, with no new therapeutic candidates disclosed in the latest quarterly reports. No material regulatory or litigation risks were identified in the most recent 10-K equivalent filing.

Analysts project 197.3% upside to a consensus price target of 880 JPY, significantly above the current market price of 296 JPY.

Cash conversion of 3.37 is best-in-class, significantly surpassing the 0.95 median for the pharmaceutical industry cohort.

The company maintains a zero debt-to-equity ratio, placing it in the top quartile for financial leverage within the cohort.

Return on equity of 2.56% falls below the 2.92% cohort median, indicating weaker capital efficiency compared to pharmaceutical peers.

Revenue declined 3.4% year-over-year to 3.7 billion JPY, marking the first annual revenue contraction in the provided dataset.

Revenue ¥860.0M, +1,3% YoY; Operating income +186,2% YoY.

• ▍Revenue ¥860.0M, +1,3% YoY
• ▍Operating income +186,2% YoY
• ▍Net income +173,9% YoY
• ▍Net margin 3.9%

Revenue ¥893.4M, −11,9% YoY; Operating income +92,0% YoY.

• ▍Revenue ¥893.4M, −11,9% YoY
• ▍Operating income +92,0% YoY
• ▍Net income +44,5% YoY
• ▍Net margin -8.5%

Revenue ¥997.6M, −10,4% YoY; Operating income −0,6% YoY.

• ▍Revenue ¥997.6M, −10,4% YoY
• ▍Operating income −0,6% YoY
• ▍Net income +1,2% YoY
• ▍Net margin 7.5%

Revenue ¥971.3M, −7,9% YoY; Operating income +5,1% YoY.

• ▍Revenue ¥971.3M, −7,9% YoY
• ▍Operating income +5,1% YoY
• ▍Net income −63,7% YoY
• ▍Net margin 5.8%

Revenue ¥849.2M; Operating income -¥59.0M.

• ▍Revenue ¥849.2M
• ▍Operating income -¥59.0M
• ▍Net margin -5.4%

Revenue ¥3.71B, −14,8% YoY; Operating income −22,7% YoY.

• ▍Revenue ¥3.71B, −14,8% YoY
• ▍Operating income −22,7% YoY
• ▍Net income −95,5% YoY
• ▍Free cash flow +110,8% YoY
• ▍Net margin 0.3%